Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar PMJ","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuneering Raises $20 Million in Oversubscribed Series A Funding","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Immuneering Corporation"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InMed Pharmaceuticals"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cronos Group"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"orgOrder":0,"company":"QliniQ","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Pharmaceuticals Expands Its Pipeline with A Product Candidate for A Mineral Deficiency in The Blood (hypophosphatemia)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"QliniQ"}]

Find Novel Drugs for Nutrition and Weight Loss under Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Global rights of the ongoing development have been licensed-in from Dutch company, QliniQ, who maintains the rights to commercialize the product candidate in its home country, and a selected number of Middle Eastern and developing countries.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The patent application is the third collaboration, each referring to the combination of SciSparc's Palmitoylethanolamide (PEA), the active ingredient of CannAmide™ and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions.

            Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Clearmind Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Ginkgo Bioworks

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            delta 9-dominant tetrahydrocannabivarin, d9-THCV is the naturally-occurring variant found in the Cannabis plant, to create unique health and wellness products.

            Lead Product(s): Tetrahydrocannabivarin

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Baymedica

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from the financing will be used to accelerate Immuneering’s pipeline including programs in cancer cachexia, next-generation KRAS inhibition and the RAF-MEK pathway.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Boxcar PMJ

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY